PA-915

• Description:

  PA-915 (PAC1R antagonist 1) (compound 3d) is a potent and orally active antagonist of PAC1 receptor. PAC1R antagonist 1 can inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) - and nerve injury-induced allodynia[1].

• Product Name Alternative:

  PAC1R antagonist 1

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  PACAP Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pac1r-antagonist-1.html

• Concentration:

  10mM

• Purity:

  99.17

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 160°C)

• Smiles:

  O=C(C1CC(N(C1)C2=NNC3=C2C=CC=C3Cl)=O)NCCC4=CNC=N4

• Molecular Formula:

  C17H17ClN6O2

• Molecular Weight:

  372.81

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Takasaki I, et, al. Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain. Eur J Med Chem. 2020 Jan 15;186:111902.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2305204-24-2]